Investors

  • 2022-03-04
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2022
  • 2022-02-09
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDE 31 JANUARY 2022
  • 2022-01-31
    RESIGNATION OF JOINT COMPANY SECRETARY
  • 2022-01-21
    ELECTION OF MEANS OF RECEIPT AND LANGUAGE OF CORPORATE COMMUNICATIONS AND REPLY FORM
  • 2022-01-21
    ELECTION OF MEANS OF RECEIPT AND LANGUAGE OF CORPORATE COMMUNICATIONS
  • 2022-01-14
    DISCLOSEABLE TRANSACTION - PATENT AND KNOW-HOW LICENSE AGREEMENT WITH A*CCELERATE
  • 2022-01-05
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2021
  • 2021-12-06
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED NOVEMBER 30, 2021
  • 2021-11-11
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON PHASE 2B STUDY OF SACITUZUMAB GOVITECAN CONDUCTED IN CHINA OF PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER MEETS PRIMARY OVERALL RESPONSE RATE ENDPOINT
  • 2021-11-08
    (1) VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE; and (2) SUPPLEMENTAL INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
 Copyright Everest Medicines 2020  云顶药业(苏州)有限公司 苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers

沪公网安备 31010602006477号